Brucellosis: A retrospective evaluation of 99 cases and review of brucellosis treatment

Tropical Doctor

Volumn 38, Issue 1, 2008, Pages 59-62

  Demirtürk, Neşe ^a,c   Demirdal, Tuna ^a   Erben, Nurettin ^b   Demir, Serap ^a   Asci, Zerrin ^a   Kilit, Turkan Pasali ^a   Kartal, Elif Doyuk ^b  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^c AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVAMISOLE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ACUTE DISEASE; ADULT; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; BLOOD CULTURE; BRUCELLA; BRUCELLOSIS; CHRONIC DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; EPIDURAL ABSCESS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEPATITIS; HUMAN; INTERVERTEBRAL DISK DEGENERATION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; ORCHITIS; OSTEOARTHROPATHY; PATIENT CODING; PREGNANT WOMAN; RASH; RECURRENT DISEASE; RETROSPECTIVE STUDY; SACROILIITIS; SEROLOGY; SPONDYLITIS; TREATMENT DURATION; TREATMENT OUTCOME; TURKEY (BIRD); UNIVERSITY HOSPITAL; DISEASE TRANSMISSION; DRUG COMBINATION; MIDDLE AGED; TURKEY (REPUBLIC);

BRUCELLA;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; BRUCELLOSIS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TURKEY;

EID: 43049176855     PISSN: 00494755     EISSN: 17581133     Source Type: Journal    
DOI: 10.1258/td.2006.006266     Document Type: Article

References (25)

1. Young EJ. Brucella species In: Mandel GL, Bennett JE, Dolin R,eds. Principles and Practice of Infectious Disease. Philadelphia Pennsylvania: Churchill Livingstone, 2005:2669-2674
2. Young EJ. An overview of human brucellosis. Clin Infect Dis 1995;21:283-290
3. The data of Turkish Ministry of Health. See www.saglik.gov.tr/extras/ istatistikler/temel2001/121.htm
4. The data of Turkish Ministry of Health. See www.saglik.gov.tr/extras/ istatistikler/temel2001/119.htm
5. Gotuzzo E, Carrillo C. Brucella. In: Gorbach SL, Bartlett JG, Blacklow NR,eds. Infectious Disease. Philadelphia: Lippincott Williams & Wilkins, 2004:1717-1724
6. Al-Shamahy HA, Whitty CJ, Wright SG. Risk factors for human brucellosis in Yemen: a case control study. Epidemiol Infect 2000;125:309-313
7. Tasbakan MI, Yamazhan T, Gökengin D, et al. Brucellosis. A retrospective evaluation. Trop Doct 2003;33:151-153
8. Taşova Y, Saltoǧlu N, Yilmaz G, İnal S, Aksu HSZ. Brucellosis: an evaluation of clinical, laboratory and treatment features of 238 adult cases. Turk J Infect 1998;12:307-312
9. Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis 1991;138:359-372
10. Navarro JM, Mendoza J, Leiva J, Rodriguez-Contreras R, de la Rosa M. C-reactive protein as a prognostic indicator in acute brucellosis. Diagn Microbiol Infect Dis 1990;13:269-270 (Pubitemid 20211490)
11. Colmenero JD, Reguara JM, Martos F, et al. Complications associated with Brucella melitensis infection: A study of 530 cases. Medicine (Baltimore)1996;75:195-211 (Pubitemid 26260237)
12. WHO, Joint Food and Agriculture Organization, World Health Organization, FAO-WHO, Expert Committee on Brucellosis (sixth report). World Health Organ Tech Rep Ser 1986;740:56-57
13. Akova M, Uzun Ö, Akalin HE, Hayran M, Ünal S, Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993;37:1831-1834 (Pubitemid 23265537)
14. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004;36:636-638 (Pubitemid 39294907)
15. Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus docyxycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis 2004;4:18 (www.biomedcentral.com/1471-1334/4/18) (Pubitemid 39637307)
16. Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimic Agents Chemother 2006;50:22-23 (Pubitemid 43042897)
17. Madkour MM. Bone and joint imaging. In: Madlour MM,ed. Brucellosis. London: Buttrworths, 1989:11-28
18. Pina MA, Ara JR, Modrego PJ, Juyol MC, Capablo JL. Brucelar epidural abscess. Eur J Neurol 1999;6:87-89
19. Pina MA, Modrego PJ, Uraz JJ, Cobeto JC, Lerm FJ, Bargess JJ. Brucellar spinal epidural abscess of cervical location: report of four cases. European Neurology 2001;45:249-253 (Pubitemid 32521043)
20. Perez MAH, Rodriguez BA, Garcia AF, Diez-Tejedor E, Tella PB. Treatment of nervous system brucellosis with rifampicin and doxycycline. Neurology 1986;36:28-31
21. Solera J, Lozano E, Martinez-Alfaro E, Espinosa A, Castillejos ML, Abad L. Brucella spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999;23:1440-1449 (Pubitemid 30022738)
22. Irmak H, Buzgan T, Karahocagil MK, Evirgen O, Akdeniz H, Demir AP. The effect of levamisole combined with the classical treatment chronic brucellosis. Tohoku J Exp Med 2003;20:221-228 (Pubitemid 38128806)
23. Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001;32:1172-1177 (Pubitemid 32390111)
24. Bodur H, Balaban N, Aksaray S, et al. Biotypes and antimicrobial susceptibilities of Brucella isolate. Scand J Infect Dis 2003;35:337-338 (Pubitemid 36889331)
25. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997;53:245-256